Noxopharm Ltd (ASX:NOX, OTC:NOXOF) CEO Dr Gisela Mautner tells Proactive a new pre-clinical product candidate from its Sofra™ technology platform, known as SOF-XX, has shown to be effective against inflammatory skin disease in pre-clinical models. The biotech company presented results from a study in partnership with Melbourne’s Hudson Institute of Medical Research at the 15th International Congress on Systemic Lupus Erythematosus (LUPUS 2023), held in Seoul, showing the new drug emerging as a promising new class of therapeutics for the treatment of autoimmune diseases such as psoriasis and lupus.
Noxopharm hails new Sofra™ drug inflammation results
